Literature DB >> 10030411

Absence of the cell cycle inhibitor p27Kip1 protein predicts poor outcome in patients with stage I-III colorectal cancer.

C Belluco1, G Esposito, R Bertorelle, A Del Mistro, A Fassina, G Vieceli, L Chieco-Bianchi, D Nitti, M Lise.   

Abstract

BACKGROUND: The p27Kip1 protein regulates the G1 to S phase transition of cell cycle by binding to and inhibiting the cyclin E/Cdk2 complex. This study explores the prognostic significance of the absence of the p27Kip1 protein in patients with colorectal cancer (CRC).
METHODS: Formalin-fixed tumor sections from 124 patients who underwent curative resection for stage I-III CRC were analyzed by immunohistochemistry using MoAb anti-p27KiP1.
RESULTS: Detectable levels of p27Kip1 protein were found in 86% of tumors. Median follow-up was 55 months. Actuarial 5-year disease-free survival (DFS) and overall survival (OS) were 76% and 85%, respectively, in patients with tumors with p27Kip1 protein expression and 34% and 40%, respectively, in those whose tumors lacked p27Kip1 protein expression (P < .001). At multivariate analysis, tumor stage (III vs. I-II) and p27Kip1 protein status (absence vs. presence) were found to be independent prognostic factors for DFS and OS.
CONCLUSIONS: Lack of p27KiP1 protein expression in CRC is a negative prognostic marker and may therefore be useful in selecting early-stage patients more likely to benefit from adjuvant treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10030411     DOI: 10.1007/s10434-999-0019-2

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  6 in total

Review 1.  Lymphangiogenesis: a new player in cancer progression.

Authors:  Masayuki Nagahashi; Subramaniam Ramachandran; Omar M Rashid; Kazuaki Takabe
Journal:  World J Gastroenterol       Date:  2010-08-28       Impact factor: 5.742

Review 2.  [Current status of the prognostic value of molecular markers in patients with colorectal cancer and the prediction of response to adjuvant therapy].

Authors:  Jose M Fernández-Cebrián; Peter Vorwald Kuborn; Mar Pardo de Lama; Alfonso Sanjuanbenito Dehesa; Manuel Nevado Santos; Pedro A Pacheco Martínez; Beatriz Fernández-Escudero
Journal:  Clin Transl Oncol       Date:  2005-04       Impact factor: 3.405

Review 3.  [Clinical, pathological and molecular prognostic factors in colorectal carcinomas].

Authors:  S E Baldus
Journal:  Pathologe       Date:  2003-01-21       Impact factor: 1.011

4.  A cohort study of p27 localization in colon cancer, body mass index, and patient survival.

Authors:  Shuji Ogino; Kaori Shima; Katsuhiko Nosho; Natsumi Irahara; Yoshifumi Baba; Brian M Wolpin; Edward L Giovannucci; Jeffrey A Meyerhardt; Charles S Fuchs
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-06       Impact factor: 4.254

5.  Loss of p27Kip1 leads to expansion of CD4+ effector memory T cells and accelerates colitis-associated colon cancer in mice with a T cell lineage restricted deletion of Smad4.

Authors:  Sung Hee Choi; Emily C Barker; Kyle J Gerber; John J Letterio; Byung-Gyu Kim
Journal:  Oncoimmunology       Date:  2020-12-03       Impact factor: 8.110

6.  Clinical significances of p27 in digestive tract cancers: a comprehensive analysis on immunohistochemistry staining, published literatures, microarray and RNA-seq data.

Authors:  Dan-Dan Xiong; Rong-Quan He; Ai-Hua Lan; Wen-Jie Chen; Yi-Huan Luo; Zhi-Hua Ye; Jie Ma; Gang Chen; Yi-Wu Dang
Journal:  Oncotarget       Date:  2018-01-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.